Iodixanol
Clinical data | |
---|---|
Trade names | Visipaque |
Other names | 5-[acetyl-[3-[acetyl-[3,5-bis(2,3-dihydroxypropylcarbamoyl)-2,4,6-triiodo-phenyl]amino]-2-hydroxy-propyl]amino]-N,N'-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-benzene-1,3-dicarboxamide |
AHFS/Drugs.com | Multum Consumer Information |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Protein binding | Negligible |
Metabolism | Excreted unchanged |
Elimination half-life | 2.1 hours |
Excretion | Kidney |
Identifiers | |
| |
JSmol) | |
| |
| |
(what is this?) (verify) |
Iodixanol, sold under the brand name Visipaque, is an iodine-containing non-ionic radiocontrast agent.[2]
It is available as a
Medical uses
The radiocontrast agent is given intravenously for computed tomography (CT) imaging of the head, body, excretory urography and venography. The radiocontrast agent is also given intra-arterially for angiography imaging.[5]
Adverse effects
About 30% of those received intravenous iodixanol injection has warmth, pain, or discomfort at the site of the injection. Other adverse effects include: taste perversion (3.5%), nausea (2.8%), and headache (2.5%).[5]
Society and culture
Available forms
The contrast can either be given intra-arterialy or intravenously.[5]
Veterinary uses
Iodixanol is also the active ingredient in a number of 'cushion' products used during the centrifugation of stallion semen. It is layered underneath the extended stallion semen allowing for a higher g force to be used with less sperm damage and better recovery rates. Post centrifugation the supernatant above and the cushion below is removed, leaving a concentrated sperm pellet in the conical tube.[6]
References
- FDA. Retrieved 22 October 2023.
- S2CID 195690679.
- ^ "2022 First Generic Drug Approvals". U.S. Food and Drug Administration (FDA). 3 March 2023. Archived from the original on 30 June 2023. Retrieved 30 June 2023.
- ^ "Competitive Generic Therapy Approvals". U.S. Food and Drug Administration (FDA). 29 June 2023. Archived from the original on 29 June 2023. Retrieved 29 June 2023.
- ^ a b c "Visipaque (iodixanol injection)" (PDF). US Food and Drug Administration. 1 September 2008. Archived from the original (PDF) on 8 April 2022.
- PMID 18573520.
External links
- https://web.archive.org/web/20160825063320/http://www.cosmobiousa.com/axis-shield-density-gradient-optiprep.html
- http://www3.gehealthcare.com/en/products/categories/contrast_media/visipaque
- https://web.archive.org/web/20110927141156/http://www.gehealthcare.com/caen/md/docs/visipaquepieng.pdf
- Iodixanol drug label/data at DailyMed from U.S. National Library of Medicine, National Institutes of Health.